Abstract | PURPOSE: METHODS: Human corneal epithelial and fibroblast cell lines and an umbilical vascular endothelial cell line were treated with increasing doses of bevacizumab. The effect of this treatment on cell viability was assessed by WST-1 and crystal violet staining assays. Cytotoxicity was also assessed by fluorescent microscopy and flow cytometric evaluation of propidium iodide-stained cells. RESULTS: In the cytotoxicity experiments, there was no difference in cell numbers after 24-hour exposure compared with control in any of the cell lines at the concentrations tested (P > 0.05 to 0.98). CONCLUSION:
Bevacizumab was nontoxic to human corneal epithelial and fibroblast cells at 3 different concentrations.
|
Authors | Kakarla V Chalam, Kakarla V Shalam, Swati Agarwal, Vikram S Brar, Ravi K Murthy, Rajesh K Sharma |
Journal | Cornea
(Cornea)
Vol. 28
Issue 3
Pg. 328-33
(Apr 2009)
ISSN: 1536-4798 [Electronic] United States |
PMID | 19387236
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Angiogenesis Inhibitors
(toxicity)
- Antibodies, Monoclonal
(toxicity)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Cell Count
- Cell Line
- Cell Proliferation
(drug effects)
- Cell Survival
(drug effects)
- Corneal Stroma
(cytology)
- Endothelium, Vascular
(drug effects)
- Epithelium, Corneal
(drug effects)
- Fibroblasts
(drug effects)
- Flow Cytometry
- Humans
- Microscopy, Fluorescence
- Umbilical Veins
(cytology)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|